MRK · Merck & Co., Inc.
$152.55
+3.56 (+2.39%)
At close · Aug 21
Market Cap
$376.37B
Shares
2.47B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$65.01B
+1.3%
FY2025
Net Income
$18.25B
+6.6%
FY2025
Gross Margin
74.8%
-1.5pp
FY2025
Diluted EPS
$7.28
+8%
FY2025
Operating Cash Flow
$16.47B
-23.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $66.57B | $65.01BG | $64.17B | $60.12BG | $59.28B | $48.7B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B | — | — | — | — | — | $45.99B | $27.43B | $23.85B | $24.2B | |
| $18B | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B | $13.62B | $12.02B | $13.51B | $12.91B | $14.03B | $14.93B | $16.77B | $16.95B | $16.45B | $16.87B | $18.4B | $9.02B | $5.58B | $6.14B | |
| $48.57B | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B | $27.9B | $27.11B | $28.79B | $27.21B | $25.78B | — | — | — | — | — | $27.59B | $18.41B | $18.27B | $18.06B | |
| — | 74.8% | 76.32% | 73.17% | 70.63% | 72.02% | 67.2% | 69.29% | 68.06% | 67.82% | 64.75% | — | — | — | — | — | 60% | 67.12% | 76.59% | 74.62% | |
| $30.45B | $15.79B | $17.94B | $30.53B | $13.55B | $12.25B | $13.4B | $9.72B | $9.75B | $10.34B | $10.26B | $6.7B | $7.18B | $7.5B | $8.17B | $8.47B | $11.11B | $5.85B | $4.81B | $4.88B | |
| $11.14B | $10.73B | $10.82B | $10.5B | $10.04B | $9.63B | $8.96B | $9.46B | $10.1B | $10.07B | $10.02B | $10.31B | $11.61B | $11.91B | $12.78B | $13.73B | $13.13B | $8.54B | $7.38B | $7.56B | |
| — | $2.8B | $2.4B | $2B | $2.1B | $1.6B | $1.8B | $1.7B | $3.1B | $3.2B | $3.8B | $4.8B | $4.2B | $4.8B | $5B | $5.1B | $4.7B | — | — | — | |
| — | — | — | — | — | — | — | $3.65B | $4.52B | $4.68B | $5.47B | $6.38B | $6.69B | $6.99B | $6.98B | $7.43B | $7.38B | $2.58B | $1.63B | $1.99B | |
| $606M | $889M | $309M | $599M | $337M | $661M | $575M | $626M | $632M | $776M | $651M | $619M | $1.01B | $1.71B | $664M | $1.31B | $985M | $1.63B | $1.03B | $327.1M | |
| $1.74B | $1.36B | $1.27B | $1.15B | $962M | $806M | $831M | $893M | $772M | $754M | $693M | $672M | $732M | $801M | $714M | $695M | $715M | $460M | $251M | — | |
| $235M | $343M | $415M | $365M | $157M | $36M | $59M | $274M | $343M | $385M | $328M | $289M | $266M | $264M | $232M | $145M | $83M | $210M | $631M | — | |
| -$430M | -$151M | $24M | -$466M | -$1.5B | $1.34B | $890M | -$129M | $402M | $500M | -$189M | -$1.53B | $11.61B | -$411M | -$1.12B | -$946M | -$1.3B | $10.67B | $2.32B | $75.2M | |
| $125M | — | — | — | — | — | — | — | — | $42M | $86M | $205M | $257M | $404M | $642M | $610M | $587M | $2.24B | $2.56B | $2.98B | |
| $5.95B | $21.07B | $19.94B | $1.89B | $16.44B | $13.88B | $5.86B | $7.17B | $8.7B | $6.52B | $4.66B | $5.4B | $17.28B | $5.55B | $8.74B | $7.33B | $1.65B | $15.29B | — | — | |
| $2.78B | $2.8B | $2.8B | $1.51B | $1.92B | $1.52B | $1.34B | $1.57B | $2.51B | $4.1B | $718M | $942M | $5.35B | $1.03B | $2.44B | $942M | $671M | $2.27B | $2B | $95.3M | |
| $3.17B | $18.25B | $17.12B | $365M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | $4.4B | $6.17B | $6.27B | $861M | $12.9B | $7.81B | $3.28B | |
| — | 28.08% | 26.68% | 0.61% | 24.49% | 26.79% | 17.02% | 25.16% | 14.71% | 5.97% | 9.85% | — | — | — | — | — | 1.87% | 47.03% | 32.74% | 13.54% | |
| -$3M | $9M | $16M | $12M | $7M | $16M | $15M | -$66M | -$27M | $24M | $21M | $17M | $14M | $113M | $131M | $120M | $121M | $123M | $124M | $121.4M | |
| $3.17B | $18.25B | $17.12B | $365M | $14.52B | $13.05B | $7.07B | $9.84B | — | — | — | — | $11.92B | $4.4B | $6.17B | $6.26B | $859M | $12.85B | $7.79B | $3.28B | |
| $4.65B | $18.91B | $17.33B | -$28M | $14.18B | $14.81B | $6.63B | $9.2B | $5.86B | $2.71B | $2.84B | $4.62B | $9.79B | $6.89B | $4.62B | $6.36B | — | — | — | — | |
| USD/shares | — | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 | $3.84 | $2.23 | $0.84 | $1.35 | $1.51 | $3.93 | $1.42 | $1.94 | $1.95 | $0.27 | $5.41 | $3.48 | $1.44 |
| USD/shares | — | $7.28G | $6.74G | $0.14G | $5.71 | $5.14 | $2.78 | $3.81 | $2.21 | $0.83 | $1.35 | $1.49 | $3.88 | $1.40 | $1.91 | $1.93 | $0.27 | $5.39 | $3.46 | $1.42 |
| shares | — | 2.5B | 2.53B | 2.54B | 2.53B | 2.53B | 2.53B | 2.57B | 2.79B | 2.86B | 2.9B | 2.95B | 3.03B | 3.11B | 3.19B | 3.22B | 3243.56 | 2.38B | 2.24B | — |
| shares | — | 2.51B | 2.54B | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.81B | 2.88B | 2.92B | 2.98B | 3.07B | 3.14B | 3.22B | 3.24B | 3269.76 | 2.38B | 2.25B | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $59.84B in buybacks, $104.24B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.36×
Peer median 6.87×
EV/EBIT
—
P/E (TTM)
122.04×
Peer median 34.16×
Peer medians compare against the 7 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceuticalsegment | $58,142,000,000 | $57,400,000,000 | $53,583,000,000 | $52,005,000,000 | $42,754,000,000 | $36,610,000,000 | $34,100,000,000 | $37,689,000,000 |
| Animal Health Segment | $6,354,000,000 | $5,877,000,000 | $5,625,000,000 | $5,550,000,000 | $5,568,000,000 | $4,703,000,000 | $4,393,000,000 | $4,212,000,000 |
| All Other Segments | — | — | — | $0 | $0 | $23,000,000 | $175,000,000 | $250,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $36,362,000,000 | $32,151,000,000 | $28,343,000,000 | $26,811,000,000 | $22,159,000,000 | $19,517,000,000 | $18,334,000,000 | $18,228,000,000 |
| Non Us | $28,134,000,000 | $31,126,000,000 | $30,865,000,000 | — | — | — | — | — |
| EMEA | $14,580,000,000 | $14,041,000,000 | $13,254,000,000 | $14,493,000,000 | $13,341,000,000 | $11,547,000,000 | $10,496,000,000 | $12,213,000,000 |
| Latin America | $3,410,000,000 | $3,459,000,000 | $3,086,000,000 | $2,582,000,000 | $2,206,000,000 | $1,890,000,000 | $2,015,000,000 | $2,415,000,000 |
| Asia Pacific | $2,983,000,000 | $3,058,000,000 | $3,225,000,000 | $3,614,000,000 | $2,407,000,000 | $2,113,000,000 | $2,126,000,000 | $2,909,000,000 |
| Other Countries | $2,878,000,000 | $2,559,000,000 | $2,104,000,000 | $2,568,000,000 | $1,221,000,000 | $1,027,000,000 | $1,275,000,000 | $1,015,000,000 |
| Japan | $2,711,000,000 | $3,280,000,000 | $3,164,000,000 | $3,629,000,000 | $2,726,000,000 | $2,602,000,000 | $2,609,000,000 | $3,212,000,000 |
| China | $1,939,000,000 | $5,494,000,000 | $6,802,000,000 | $5,191,000,000 | $4,378,000,000 | $2,751,000,000 | $2,180,000,000 | $2,184,000,000 |
| International | — | $31,126,000,000 | $30,865,000,000 | $30,744,000,000 | $26,163,000,000 | $21,819,000,000 | $20,333,000,000 | $23,923,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Keytruda | $31,641,000,000 | $29,482,000,000 | $25,011,000,000 | $20,937,000,000 | $17,186,000,000 | $14,380,000,000 | $11,084,000,000 | $7,171,000,000 |
| Gardasil Gardasil 9 | $5,233,000,000 | $8,583,000,000 | $8,886,000,000 | $6,897,000,000 | $5,673,000,000 | $3,938,000,000 | $3,737,000,000 | $3,151,000,000 |
| Livestock | $3,896,000,000 | $3,462,000,000 | $3,337,000,000 | $3,300,000,000 | $3,295,000,000 | $2,939,000,000 | $2,784,000,000 | $2,630,000,000 |
| Other Pharmaceutical | $2,917,000,000 | $2,590,000,000 | $2,546,000,000 | $2,462,000,000 | $2,516,000,000 | $2,202,000,000 | $2,873,000,000 | $4,546,000,000 |
| Companion Animals | $2,458,000,000 | $2,415,000,000 | $2,288,000,000 | $2,250,000,000 | $2,273,000,000 | $1,764,000,000 | $1,609,000,000 | $1,582,000,000 |
| ProQuad MMRII Varivax | $2,451,000,000 | $2,485,000,000 | $2,368,000,000 | $2,241,000,000 | $2,135,000,000 | $1,878,000,000 | $2,275,000,000 | $1,798,000,000 |
| Bridion | $1,841,000,000 | $1,764,000,000 | $1,842,000,000 | $1,685,000,000 | $1,532,000,000 | $1,198,000,000 | $1,131,000,000 | $917,000,000 |
| Januvia | $1,604,000,000 | $1,334,000,000 | $2,189,000,000 | $2,813,000,000 | $3,324,000,000 | $3,306,000,000 | $3,482,000,000 | $3,686,000,000 |
| Alliance Revenue Lynparza | $1,450,000,000 | $1,311,000,000 | $1,199,000,000 | $1,116,000,000 | $989,000,000 | $725,000,000 | $444,000,000 | $187,000,000 |
| Winrevair | $1,443,000,000 | $419,000,000 | $0 | $0 | — | — | — | — |
| Lenvima | $1,053,000,000 | $1,010,000,000 | $960,000,000 | $876,000,000 | $704,000,000 | $580,000,000 | $404,000,000 | $149,000,000 |
| Prevymis | $978,000,000 | $785,000,000 | $605,000,000 | $428,000,000 | $370,000,000 | $281,000,000 | $165,000,000 | $72,000,000 |
| Janumet | $940,000,000 | $935,000,000 | $1,177,000,000 | $1,700,000,000 | $1,964,000,000 | $1,971,000,000 | $2,041,000,000 | $2,228,000,000 |
| Vaxneuvance | $825,000,000 | $808,000,000 | $665,000,000 | $170,000,000 | $3,000,000 | — | — | — |
| Capvaxive | $759,000,000 | $97,000,000 | $0 | — | — | — | — | — |
| Welireg | $716,000,000 | $509,000,000 | $218,000,000 | $123,000,000 | $13,000,000 | — | — | — |
| Rotateq | $673,000,000 | $711,000,000 | $769,000,000 | $783,000,000 | $807,000,000 | $797,000,000 | $791,000,000 | $728,000,000 |
| Alliance Revenue Reblozyl | $525,000,000 | $371,000,000 | $212,000,000 | — | — | — | — | — |
| Alliance Revenue Adempas Verquvo | $470,000,000 | $415,000,000 | $367,000,000 | $341,000,000 | $342,000,000 | $281,000,000 | $204,000,000 | — |
| Lagevrio | $380,000,000 | $964,000,000 | $1,428,000,000 | $5,684,000,000 | $952,000,000 | $0 | — | — |
| Isentress Isentress HD | $325,000,000 | $394,000,000 | $483,000,000 | $633,000,000 | $769,000,000 | $857,000,000 | $975,000,000 | $1,140,000,000 |
| Adempas | $312,000,000 | $287,000,000 | $255,000,000 | $238,000,000 | $252,000,000 | $220,000,000 | $215,000,000 | $190,000,000 |
| Zerbaxa | $312,000,000 | $252,000,000 | $218,000,000 | $169,000,000 | -$1,000,000 | $130,000,000 | $121,000,000 | $87,000,000 |
| Delstrigo | $306,000,000 | $249,000,000 | $201,000,000 | $151,000,000 | — | — | — | — |
| Dificid | $247,000,000 | $340,000,000 | $302,000,000 | $263,000,000 | $175,000,000 | $110,000,000 | — | — |
| Belsomra | $186,000,000 | $222,000,000 | $231,000,000 | $258,000,000 | $318,000,000 | $327,000,000 | $306,000,000 | $260,000,000 |
| Ohtuvayre | $178,000,000 | $0 | $0 | — | — | — | — | — |
| Pifeltro | $171,000,000 | $163,000,000 | $142,000,000 | $118,000,000 | — | — | — | — |
| Pneumovax23 | $166,000,000 | $263,000,000 | $412,000,000 | $602,000,000 | $893,000,000 | $1,087,000,000 | $926,000,000 | $907,000,000 |
| Keytruda Qlex | $40,000,000 | $0 | $0 | — | — | — | — | — |
| Remicade | $0 | $114,000,000 | $187,000,000 | $207,000,000 | $299,000,000 | $330,000,000 | $411,000,000 | $582,000,000 |
| Simponi | $0 | $543,000,000 | $710,000,000 | $706,000,000 | $825,000,000 | $838,000,000 | $830,000,000 | $893,000,000 |
| Alliance Revenue — Adempas | — | — | — | — | — | — | $204,000,000 | $139,000,000 |
| Arcoxia | — | — | — | — | — | — | $288,000,000 | $335,000,000 |
| Atozet | — | — | — | — | — | — | $391,000,000 | $347,000,000 |
| Cancidas | — | — | — | $174,000,000 | $212,000,000 | $213,000,000 | $249,000,000 | $326,000,000 |
| Cozaar Hyzaar | — | — | — | — | — | — | $442,000,000 | $453,000,000 |
| Cubicin | — | — | — | — | — | — | $257,000,000 | $367,000,000 |
| Emend | — | — | — | — | — | — | $388,000,000 | $522,000,000 |
| Follistim Aq | — | — | — | — | — | — | $241,000,000 | $268,000,000 |
| Implanon Nexplanon | — | — | — | — | — | — | $787,000,000 | $703,000,000 |
| Invanz | — | — | — | $189,000,000 | $202,000,000 | $211,000,000 | $263,000,000 | $496,000,000 |
| Molnupiravir | — | — | — | — | $952,000,000 | — | $0 | — |
| Nasonex | — | — | — | — | — | — | $293,000,000 | $376,000,000 |
| Noxafil | — | $177,000,000 | $213,000,000 | $238,000,000 | $259,000,000 | $329,000,000 | $662,000,000 | $742,000,000 |
| Nuvaring | — | — | — | — | — | — | $879,000,000 | $902,000,000 |
| Primaxin | — | — | $213,000,000 | $239,000,000 | $259,000,000 | $251,000,000 | $273,000,000 | $265,000,000 |
| Reblozyl | — | $371,000,000 | $212,000,000 | $166,000,000 | $17,000,000 | $0 | — | — |
| Singulair | — | — | — | — | — | — | $698,000,000 | $708,000,000 |
| Vaqta | — | — | $180,000,000 | $173,000,000 | $179,000,000 | $170,000,000 | $238,000,000 | $239,000,000 |
| Vytorin | — | — | — | — | — | — | $285,000,000 | $497,000,000 |
| Zepatier | — | — | — | — | — | — | $370,000,000 | $455,000,000 |
| Zetia | — | — | — | — | — | — | $590,000,000 | $857,000,000 |
Key facts
CIK
310158
CUSIP
58933Y105
13F (30d)
2751 filings
2653 filers
Visit website
Investor relations